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Breast cancer (BC) is a heterogeneous disease, and different tumor characteristics and genetic variation may affect the clin-
ical outcome. The FANCM c.5101C> T nonsense mutation in the Finnish population associates with increased risk of breast
cancer, especially for triple-negative breast cancer patients. To investigate the association of the mutation with disease
prognosis, we studied tumor phenotype, treatment outcome, and patient survival in 3,933 invasive breast cancer patients,
including 101 FANCM c.5101C> T mutation carriers and 3,832 non-carriers. We also examined association of the mutation
with nuclear immunohistochemical staining of DNA repair markers in 1,240 breast tumors. The FANCM c.5101C> T mutation
associated with poor 10-year breast cancer-specific survival (hazard ratio (HR)51.66, 95% confidence interval (CI) 1.09–
2.52, p50.018), with a more pronounced survival effect among familial cases (HR52.93, 95% CI 1.5–5.76, p51.80 3
1023). Poor disease outcome of the carriers was also found among the estrogen receptor (ER) positive subgroup of patients
(HR51.8, 95% CI 1.09–2.98, p50.021). Reduced survival was seen especially among patients who had not received radio-
therapy (HR53.43, 95% CI 1.6–7.34, p51.5031023) but not among radiotherapy treated patients (HR51.35, 95% CI
0.82–2.23, p50.237). Significant interaction was found between the mutation and radiotherapy (p50.040). Immunohisto-
chemical analyses show that c.5101C> T carriers have reduced PAR-activity. Our results suggest that FANCM c.5101C> T
nonsense mutation carriers have a reduced breast cancer survival but postoperative radiotherapy may diminish this survival
disadvantage.
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chemistry; KBCP: Kuopio breast cancer project; NHEJ: non-homologous end joining; PARP: poly(ADP-ribose) polymerase; PR: proges-
terone receptor; SSB: single strand break; TNBC: triple-negative breast cancer
Additional Supporting Information may be found in the online version of this article.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or
adaptations are made.
This article was published online on 19 September 2016. An error was subsequently identiﬁed. This notice is included in the online and print
versions to indicate that both have been corrected on 26 September 2016.
Disclosure: The authors have declared no conﬂicts of interest.
DOI: 10.1002/ijc.30394
History: Received 30 Mar 2016; Accepted 19 July 2016; Online 20 Aug 2016
Correspondence to: Dr. Heli Nevanlinna, Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Biomedicum
Helsinki, PO Box 700, 00029 HUS, Finland, Tel.: 1358 9 4717 1750, Fax: 1358 9 4717 1751, E-mail: heli.nevanlinna@hus.ﬁ
C
an
ce
r
G
en
et
ic
s
an
d
E
pi
ge
n
et
ic
s
Int. J. Cancer: 139, 2760–2770 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
International Journal of Cancer
IJC
Breast cancer is the most common cancer among women
worldwide, and also the leading cause of female cancer
death.1 Most breast cancer cases are sporadic, but around
15% have familial background. Hereditary predisposition to
breast cancer is caused by variation in multiple genes com-
monly involved in DNA repair, especially with homologous
recombination repair pathway.2 Recently, we identiﬁed a new
breast cancer allele in the Finnish population in the FANCM
gene, that functions in the Fanconi Anemia (FA) DNA repair
pathway. The FANCM c.5101C>T (p.Q1701X, rs147021911)
nonsense mutation increased the risk of breast cancer over
twofold, and 3.5-fold increased frequency was seen among
the triple-negative breast cancer (TNBC) cases.3
Predisposing mutations may associate with speciﬁc breast
cancer phenotype or subgroup, as well as with patient prog-
nosis and treatment outcome. CHEK2 and PALB2 truncating
mutations, as well as FANCM c.5101C>T mutation, confer
moderate risk for breast cancer, with a higher risk among
patients with family history of breast cancer.3–7
CHEK2 c.1100delC and PALB2 c.1592delT mutations are
associated also with an increased risk of breast cancer death
or second breast cancer. Among patients with ER positive
breast cancer, CHEK2 c.1100delC heterozygosity is associated
with 1.6-fold risk of breast cancer speciﬁc death and 3.5-fold
risk of a second breast cancer.8,9 A signiﬁcant proportion of
PALB2 tumors are triple-negative and the PALB2 mutation
carriers have about 2-fold increased risk of breast cancer
death, independently of the triple-negative status.7,10
Here, we studied tumor characteristics, patient survival,
and treatment outcome associated with the FANCM
c.5101C>T mutation among 3,933 breast cancer patients in
four breast cancer patient series from Finland. In addition,
we examined the nuclear immunohistochemical staining of
DNA repair markers in the mutation carrier and non-carrier
tumors from 1,240 invasive breast cancer cases.
Material and Methods
Subjects
Helsinki breast cancer series. The unselected breast cancer
patient samples from Helsinki were collected at Helsinki Uni-
versity Central Hospital. From this cohort, 884 samples,
including 79% of all consecutive, newly diagnosed breast can-
cer cases during the collection periods were collected at
Department of Oncology in 1997–1998 and 2000.11,12 In
addition, 986 samples, including 87% of all consecutive, new-
ly diagnosed breast cancer cases were collected at Department
of Surgery in 2001–2004.13 Of these series, 397 cases had
family history of breast cancer.
Additional familial breast cancer series was collected at
Helsinki University Central Hospital Departments of Oncolo-
gy and Clinical Genetics.13,14 When combining the unselected
and the additional familial samples, 524 patients had strong
family history with at least three breast or ovarian cancers
among ﬁrst or second degree relatives (including the pro-
band) and 568 patients had at least one ﬁrst degree relative
affected with breast or ovarian cancer. All the patients with
strong family history were tested negative for BRCA1/2 muta-
tions and the patients with one affected relative were tested
negative for Finnish BRCA1/2 founder mutations as previous-
ly described.5,15,16 Only invasive cases were included in the
analyses (N5 2,337).
All samples are genomic DNA isolated from peripheral
blood. The patient genealogies were conﬁrmed with popula-
tion registries or hospital records and cancer diagnoses
through the hospital records and the Finnish Cancer Registry.
ER and progesterone hormone receptor (PR) status (positive
when >10% of cells were stained) and tumor histology infor-
mation were collected from pathology reports, HER2-status is
based on immunohistochemistry and gene ampliﬁcation as
described earlier.17–19 Information on breast cancer death
was obtained from the Finnish Cancer Registry.
Tampere breast cancer series. The unselected breast cancer
patient samples from Tampere area were collected in 1997–
1999 and additional 336 incident cases in 1996–2004 at Tam-
pere University Hospital as previously described.11,13 Only
invasive cases were included in the analysis (N5 650). All
samples are genomic DNA isolated from peripheral blood.
ER and PR hormone receptor status (positive when >10% of
cells were stained), HER2-status, and other clinicopathologi-
cal information was obtained from patient and pathology
reports and information on breast cancer death from the
Finnish Cancer Registry.
Oulu breast cancer series. The unselected breast cancer
patient samples from Northern Finland were collected at the
Oulu University Hospital between the years 2000 and 2007.
Only invasive cases were included in the analysis (N5 516).
All samples are genomic DNA isolated from peripheral
What’s new?
Variations in DNA repair genes can predispose individuals to breast cancer, with one example being FANCM c.5101C> T, a
nonsense mutation in the Fanconi Anemia DNA repair pathway. In previous work, FANCM c.5101C> T was associated with
increased breast cancer risk in the Finnish population. Here, the mutation is further shown to be associated with adverse
breast cancer outcome. Mutation-positive Finnish patients exhibited reduced long-term survival and increased risk of disease
recurrence. Survival was worse particularly for patients who were not treated with radiotherapy, indicating that FANCM
c.5101C>T may interact with radiotherapy to improve disease outcome in mutation carriers.
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blood. HER2-status was studied by means of immunohisto-
chemistry (positivity deﬁned as weak, moderate or strong lev-
els of staining and negativity completely negative staining)
and chromogenic in situ hybridization (CISH). ER and PR
hormone receptor status (positive when >10% of cells were
stained) and tumor histology information was collected from
the pathology reports as described earlier.20,21 Information on
breast cancer death was obtained from the Oulu University
Hospital.
Kuopio breast cancer series. For this study a sample set
was used from The Kuopio Breast Cancer Project (KBCP), a
prospective population-based case-control study conducted in
1990–1995. Women entering Kuopio University Hospital due
to breast symptoms were invited to take part in the study at
their ﬁrst visit to the hospital. Altogether 516 women out of
1,919 were eventually diagnosed to have breast cancer. Hos-
pital registries were used to collect information concerning
clinicopathological features of the breast cancer, surgical and
oncological treatments, and follow-up.22,23 ER and PR hor-
mone receptors were classiﬁed as positive if the percentage of
positive cells with nuclear staining was 10%. HER2 status
assessment was conducted by immunohistochemistry (IHC).
Samples with IHC score 21 or 31 were classiﬁed as HER2
positive (HER21). Altogether, 430 female patients with inva-
sive breast cancer were included in the survival analysis. All
samples are genomic DNA isolated from peripheral blood.
This study was performed with informed consent from
the patients and permission from the ethics committees of
Helsinki University Hospital, Oulu University Hospital, Tam-
pere University Hospital, University of Eastern Finland, and
Kuopio University Hospital Board on Research Ethics.
Genotyping
FANCM c.5101C>T genotyping for the Helsinki and Tam-
pere sample sets was performed with Sequenom MassARRAY
system as previously described3 and for Oulu and Kuopio
sample sets by using PCR-based high resolution melt
(HRM)—analysis and Sanger sequencing. The HRM PCR
reactions were performed in 96 well plates using Type-it
HRM PCR Kit (Qiagen, Hilden, Germany) and CFX96 Real-
Time PCR Detection System (CFX96, Bio-Rad, Hercules,
CA). Primers used for the genotyping and sequencing
FANCM c. 5101C>T mutation for Oulu and Kuopio cohorts
were: F: 5’TCAAGTGAGGAGGAGAACAATG3’, R: 5’TCA
GCGATGTCTGTTTGCTC3’.
Statistical Analyses
All four datasets including altogether 3,933 invasive breast
cancer patients from Helsinki, Tampere, Oulu, and Kuopio
areas of Finland, were pooled for statistical analyses. All sta-
tistical analyses were performed using the R version 3.0.2 sta-
tistical software (http://www.r-project.org/). Kaplan–Meier
survival curves and uni and multivariate Cox’s proportional
hazard models were used to estimate the hazard ratios and
conﬁdence intervals for survival and forest plots were drawn
for visualization. All analyses were stratiﬁed by the study.
The primary end point of the survival analyses was breast
cancer death with 10-year follow-up time. In addition, 5-year
survival analysis with local recurrence as an endpoint was
used for survival analyses in the radiotherapy-based sub-
groups in the Helsinki data set (N5 2,337), where the infor-
mation about local recurrence of the disease was available.
Time-to-event was calculated from the date of the patient
diagnosis and to account for the latency between diagnosis
and recruitment into the study, all follow-up times were left-
truncated. Cases with missing data were excluded from the
analyses.
The multivariate analyses included the common clinically
relevant factors (ER, grade, tumor size, nodal status) and/or
cancer treatments (radiotherapy, endocrine therapy, and che-
motherapy) as categorical co-variates and were stratiﬁed by
the study; inclusion of the study as a categorical co-variate
did not affect the result. In addition, the FANCM
c.5101C>T genotype from the pooled data set was ﬁtted
into two Cox’s proportional hazard models in order to test
the interaction between the mutation and radiotherapy treat-
ment. One model included the treatment and FANCM
c.5101C>T genotype as individual covariates and the other
included an interaction term between these two. Two-way
anova was used as a likelihood-ratio test to compare the two
models.24,25
The p-values for comparisons of histopathological features
of mutation carriers and non-carriers were calculated with
Pearson’s chi squared test or Fisher exact test (for n 5).
Logistic regression was used for histopathological features
with more than two categories. p-values <0.05 were consid-
ered statistically signiﬁcant.
To test whether FANCM mutation status correlates with
immunohistochemical expression of markers involved in
DNA damage response and repair, we analyzed a number of
markers that have been stained and scored as described in
our previous studies: BRCA1, FANCD2, RAD51, XPF,
PAR26; ATM,18 gamma-HA2X,27 and TP53.28 For the contin-
uously scored markers (BRCA1, FANCD2, RAD51, XPF, and
PAR; % positive nuclei and staining intensity score as deter-
mined by automated analysis), association with FANCM
mutation status was tested using a Kruskal–Wallis test. All
other markers used categorical scoring and a v2 test was
employed as the test for association. Further information is
available in Supporting Information Appendix.
Results
All survival analysis results are based on the 3,933 invasive
breast cancer cases in the pooled data set with 581 breast
cancer deaths, except the survival analysis among
radiotherapy-based subgroups with local recurrence as an
endpoint is based on the Helsinki data set with 2,337 invasive
samples, including 344 breast cancer deaths. The pooled data
set includes 101 FANCM c.5101C>T mutation carriers and
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3,832 non-carriers, Helsinki data set includes 61 mutation
carriers and 2,276 non-carriers. The tumor characteristics of
the patients and detailed description of all the datasets used
are presented in Table 1.
Histopathological Features of the FANCM C.5101C> T
Positive Tumors
The association of the FANCM c.5101C>T mutation with
histopathological features of the tumors was studied in the
pooled data among all cases and separately among ER posi-
tive cases (Table 2). The mutation did not associate with any
common clinical feature, however the breast tumors from the
c.5101C>T mutation carriers were more often of triple neg-
ative phenotype (p5 0.060, compared with tumors from
non-carriers).
FANCM C.5101C> T Mutation Associates with Breast
Cancer Survival
To evaluate the association of the FANCM c.5101C>T
mutation with the disease outcome, we examined 10-year
breast cancer speciﬁc survival by Cox’s univariate proportion-
al hazard analysis in 3,933 invasive breast cancer patients
from Helsinki, Tampere, Oulu, and Kuopio data sets. The
mutation was associated with poor breast cancer-speciﬁc sur-
vival in the pooled data set stratiﬁed for study (HR5 1.66,
95% CI 1.09–2.52, p5 0.018). Absolute uncorrected survival
rates are illustrated in Figure 1a. However, in the multivariate
survival analysis including the common clinical features (ER,
grade, tumor size, nodal status) and the conventional cancer
treatments (radiotherapy, chemotherapy, endocrine treat-
ment) the mutation was not signiﬁcantly and independently
prognostic in the pooled data set (HR5 1.44, 95% CI 0.91–
2.26, p5 0.133) (Supporting Information Table 1).
As the mutation associates with triple-negative phenotype
with poor survival as such, we analyzed the survival speciﬁ-
cally also among ER positive cases. The mutation associated
with reduced survival also in the ER-positive group of
patients in the pooled data set stratiﬁed for study (HR5 1.8,
95% CI 1.09–2.98, p5 0.021). Absolute uncorrected survival
rates are illustrated in Figure 1b. Furthermore, as the
FANCM c.5101C>T mutation associates with familial breast
cancer risk, we performed the survival analysis for the inva-
sive familial cases (N5 1,006) among the Helsinki dataset in
which familial status was available for the samples. The
breast cancer speciﬁc survival was worse for mutation carriers
among patients with family history of the disease (HR5 2.93,
95% CI 1.5–5.76, p5 1.80 3 1023; Fig. 1c).
Survival in Subgroups Defined by Tumor Phenotype
and Treatment
To examine the survival effect of the FANCM c.5101C>T
mutation in more detail, we performed univariate Cox’s pro-
portional hazard analysis (endpoint: breast cancer death in
10 years) in subgroups based on the tumor phenotype (ER,
PR, TN, nodal status, tumor size, grade) among the pooled
data set (N5 3,933). In addition, we performed univariate
Cox’s proportional hazard analysis by the conventional can-
cer treatment options (endocrine treatment, radiotherapy,
and/or chemotherapy) to examine the treatment outcome of
the FANCM c.5101C>T mutation carriers. Forest plot was
drawn for visualizing hazard ratios and conﬁdence intervals
(Fig. 2). As the worse survival was also seen among the ER-
positive patients, we performed similar subgroup analyses
(PR, TN, nodal status, tumor size, grade, and the anticancer
treatments) among ER-positive patients (N5 3,013) (Sup-
porting Information Fig. 1). Heterogeneity in the survival
effect was seen for the c.5101C>T mutation carriers related
to radiotherapy treatment, with signiﬁcantly reduced survival
especially among patients who had not received radiotherapy
(HR5 3.43, 95% CI 1.6–7.34, p5 1.50 3 1023) but not
among radiotherapy treated patients (HR5 1.35, 95% CI
0.82–2.23, p5 0.237).
To further examine the radiotherapy outcome among the
c.5101C>T carriers, we performed survival analysis with
local recurrence (within 5 years) as an endpoint in the Hel-
sinki data set where the recurrence information was available
(N5 2,337). Increased risk for local recurrence was observed
for mutation carriers who had not received radiotherapy
(HR5 6.19, 95% CI 1.46–26.2, p5 0.013, Supporting Infor-
mation Table 2) but not among radiotherapy treated patients
(HR5 0.98, 95% CI5 0.24–4.00, p5 0.979). In the multivari-
ate model, the FANCM c.5101C>T mutation is only border-
line signiﬁcant (p5 0.086), however the hazard ratios remain
consistent.
Next, we tested interaction between FANCM c.5101C>T
genotype and radiotherapy treatment with Cox’s proportional
hazard model stratiﬁed with study among pooled data set,
including 2,996 patients who had received radiotherapy and
864 who had not (Table 3A). A signiﬁcant interaction was
seen between the mutation and radiotherapy treatment
(p5 0.032), with a protective hazard ratio (HR5 0.37, 95%
CI 0.15–0.92). A likelihood-ratio test comparing models with
interaction term and model with independent covariates dis-
played an interactive effect between the covariates (p(inter-
action)50.040). These results suggest that FANCM-mutation
positive breast cancer patients may beneﬁt from radiotherapy
more than non-carriers, an issue that should be further inves-
tigated to clarify the absolute beneﬁts from radiotherapy to
such patients.
We further studied the survival interaction of FANCM
mutation with radiotherapy using similar interaction model
with local recurrence (within 5 years) as an endpoint in the
Helsinki data set (N5 2,069) (Table 3B). Due to the smaller
sample size and thus loss of statistical power, the signiﬁcance
of the interactive effect is not apparent (likelihood-ratio test
p values 0.090). However, even more pronounced protective
hazard ratio was seen for FANCM c.5101C>T mutation and
radiotherapy interaction (HR5 0.16), compared to signiﬁ-
cantly increased hazard ratio for mutation alone (HR5 5.96).
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Table 1. Description of the patient data sets used in this study
Helsinki Tampere Oulu Kuopio
No. of cases 2,337 650 516 430
No. of mutation carriers 61 (2.6%) 26 (4%) 5 (1%) 9 (2%)
Vital status
Alive 1,482 (64%) 448 (69%) 362 (70%) 176 (41%)
Deceased: all-cause 511 (21%) 118 (18%) 94 (18%) 161 (37%)
Deceased: breast cancer 344 (15%) 84 (13%) 60 (12%) 93 (22%)
Follow-up mean 6SD (years) 8.1662.4 7.4462.13 5.1762.92 7.7863.08
Age at diagnosis, mean [range] 56.3 [21–95] 58.9 [30–88] 57.4 [28–92] 58.1 [23–91]
Estrogen receptor
Negative 430 (18%) 128 (20%) 96 (19%) 101 (23%)
Positive 1,803 (77%) 508 (78%) 385 (75%) 300 (70%)
Missing data 104 (5%) 14 (2%) 35 (7%) 29 (7%)
Grade
1 580 (25%) 197 (30%) 76 (15%) 115 (27%)
2 980 (42%) 226 (35%) 212 (41%) 196 (46%)
3 651 (28%) 133 (20%) 177 (34%) 115 (27%)
Missing data 126 (5%) 94 (14%) 51 (10%) 4 (1%)
T/tumor size category
1 1,409 (60%) 401 (62%) 238 (46%) 229 (53%)
2 743 (32%) 213 (33%) 226 (44%) 161 (37%)
3 69 (3%) 24 (4%) 15 (3%) 23 (5%)
4 82 (4%) – – 17 (4%)
Missing data 34 (1%) 12 (2%) 37 (7%) –
N (nodal metastasis)
Negative 1,263 (54%) 390 (69%) 265 (51%) 251 (58%)
Positive 1,036 (44%) 260 (40%) 216 (42%) 171 (40%)
Missing data 38 (2%) – 35 (7%) 8 (2%)
M (distant metastasis)
Negative 2,253 (96.5%) 630 (97%) 492 (95%) 419 (97%)
Positive 73 (3%) 12 (2%) 24 (5%) 11 (3%)
Missing data 11 (0.5%) 8 (1%) – –
Histological type
Ductal 1,597 (68%) 537 (83%) 371 (71%) 281 (65%)
Lobular 470 (20%) 86 (13%) 78 (15%) 73 (17%)
Medullar 29 (1%) – 2 (1%) 8 (2%)
Other 240 (10%) 18 (3%) 30 (6%) 68 (16%)
NA 1 9 (1%) 35 (7%) –
Radiotherapy
Yes 1,829 (78%) 493 (76%) 423 (82%) 251 (58%)
No 443 (19%) 155 (24%) 87 (17%) 179 (42%)
Missing data 65 (3%) 2 6 (1%) –
Chemotherapy
Yes 870 (37%) 131 (20%) 215 (42%) 83 (19%)
No 1,405(60%) 511 (79%) 297 (58%) 347 (81%)
Missing data 62 (3%) 8 (1%) 4 (1%) –
Endocrine therapy
Yes 1,055 (45%) 204 (32%) 243 (47%) 105 (24%)
No 1,207 (52%) 444 (68%) 268 (52%) 325 (76%)
Missing data 65 (3%) 2 5 (1%) –
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Table 2. Histopathological features of FANCM c.5101C> T-mutation carriers and wild type tumors
Category FANCM c.5101C>T % FANCM wt % p Model
All breast cancer cases
Grade 0.263 Logistic regression
1 25 26.00% 943 26.00%
2 36 37.00% 1,578 44.00%
3 36 37.00% 1,040 30.00%
T 0.255 Logistic regression
1 53 53.00% 2,224 59.00%
2 41 41.00% 1,302 34.50%
3 2 2.00% 129 3.00%
4 4 4.00% 95 2.50%
N 0.380 Pearson chisq.
neg 52 52.00% 2,117 56.20%
pos 48 48.00% 1,653 43.80%
M 0.770 Fisher
neg 99 99.00% 3,695 96.90%
pos 2 1.00% 118 3.10%
ER 0.432 Pearson chisq.
neg 23 23.00% 726 19.80%
pos 77 77.00% 2,936 80.20%
PR 0.380 Pearson chisq.
neg 39 39.00% 1,271 34.80%
pos 61 61.00% 2,386 65.20%
Her2 0.167 Pearson chisq.
neg 67 90.50% 2,336 91.50%
pos 7 9.50% 422 8.50%
TN 0.060 Pearson chisq.
TN 13 14.00% 297 8.50%
NOT TN 80 86.00% 3,215 91.50%
Morphology 0.366 Logistic regression
Ductal 78 77.00% 2,708 71.50%
Lobular 14 14.00% 693 18.30%
Medullar 1 1.00% 38 1.00%
Other 8 8.00% 348 9.20%
ER-positive breast cancer cases
Grade 0.813 Logistic regression
1 25 33.50% 874 31.50%
2 33 44.00% 1,379 49.50%
3 17 22.50% 524 19.00%
T 0.279 Logistic regression
1 45 57.00% 1,827 63.00%
2 27 35.00% 934 32.00%
3 1 3.00% 87 3.00%
4 4 5.00% 67 2.00%
N 0.500 Pearson chisq.
neg 40 52.50% 1,265 43.50%
pos 36 47.50% 1,644 46.50%
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Immunohistochemical Analyses
In the association analysis between FANCM c.5101C>T
mutation status and DNA repair related immunohistochemi-
cal markers, a statistically signiﬁcant association was detected
between nuclear poly-ADP-ribose (PAR; a measurement of
PARP activity) staining and mutated FANCM. PAR staining
was reduced in FANCM c.5101C>T mutation carrier
tumors, both in terms of the proportion of positively stained
tumor nuclei (p5 0.016, Kruskal-Wallis test) and staining
intensity (p5 0.011, Kruskal–Wallis test) (Supporting Infor-
mation Fig. 2). No other immunohistochemical markers were
associated with mutated FANCM (Supporting Information
Table 3).
Discussion
This study evaluated the survival association, tumor charac-
teristics, and treatment outcome for Finnish breast cancer
patients carrying the FANCM c.5101C>T mutation. We
detected an association between the FANCM c.5101C>T
mutation and adverse breast cancer outcome (HR5 1.66,
95% CI 1.09 – 2.52, p5 0.018, N5 3,832 [non-carriers],
N5 101 [mutation carriers]). The breast cancer speciﬁc sur-
vival was worse among familial cases (HR5 2.93, 95% CI
1.5–5.76, p5 1.80 3 1023, N5 981 [non-carriers], N5 25
[mutation carriers]).
When examining the tumors of the FANCM c.5101C>T
mutation carriers, a borderline signiﬁcant association of the
mutation was seen with triple-negative tumors (p5 0.060,
compared with tumors from non-carriers). This is in line
with the previous risk analysis, in which the FANCM
c.5101C>T mutation was found to be associated with 3.6-
fold increased risk for triple-negative subtype of breast can-
cer.3 This type of breast cancer is generally aggressive with
poor prognosis and no effective therapies available.29 Howev-
er, our survival analysis indicates that the poor prognosis
associated with FANCM c.5101C>T mutation is not only a
result of the higher incidence of the triple-negative tumors,
as the mutation also associates with worse survival among
the ER-positive subgroup of patients. Yet in the multivariate
survival analysis including conventional prognostic markers
and treatments, the FANCM c.5101C>T mutation was not
independently prognostic (HR5 1.44, 95% CI 0.91-2.26,
p5 0.133).
The comprehensive survival analyses revealed an associa-
tion with FANCM c.5101C>T mutation and radiotherapy
outcome. Interaction analyses with a hazard ratio of 0.37
(95% CI 0.15–0.95, p5 0.032) for the mutation:radiotherapy
interaction compared to the HR of 3.72 for the mutation
alone (95% CI 1.74–7.95, p5 7.00 3 1024) in the interaction
model indicate that the mutation carriers may beneﬁt from
radiotherapy. To this end, we performed the interaction anal-
yses also with local recurrence in ﬁve years as an endpoint,
as radiotherapy is commonly used to prevent such events.
While this interaction model is not statistically signiﬁcant in
the smaller sample set, the more pronounced protective haz-
ard ratio of 0.16 for the radiotherapy and FANCM
c.5101C>T interaction further supports our observations
that carrying the FANCM c. 5101C>T mutation increases
the risk for local recurrence and subsequently also death
from breast cancer, however the mutation carriers seem to
beneﬁt from postoperative radiotherapy. From the pathobio-
logical point of view, we propose that the increased risk of
local recurrence and death may reﬂect enhanced genomic
Table 2. Histopathological features of FANCM c.5101C> T-mutation carriers and wild type tumors (Continued)
Category FANCM c.5101C>T % FANCM wt % p Model
M 0.775 Fisher
neg 76 98.70% 2,841 98.00%
pos 1 1.30% 65 2.00%
PR 0.754 Pearson chisq.
neg 17 22.00% 604 20.00%
pos 60 88.00% 2,326 80.00%
Her2 1 Fisher
neg 52 91.00% 1,943 90.00%
pos 5 9.00% 219 10.00%
Morphology 0.587 Logistic regression
Ductal 56 73.00% 2,007 68.00%
Lobular 14 18.00% 635 22.00%
Medullar 0 0.00% 4 0.00%
Other 7 9.00% 286 10.00%
Abbreviations: T: tumor size class; M: distant metastasis; ER: estrogen receptor; PR: progesterone receptor
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instability and hence aggressiveness due to impaired DNA
repair in the tumors with the FANCM c. 5101C>T muta-
tion. On the positive side, such enhanced genetic instability
and suboptimal repair capacity seem to represent a speciﬁc
vulnerability of such tumors, manifest particularly after an
extra burden of difﬁcult-to repair DNA damage caused by
ionizing radiation treatment. Overall, these results are espe-
cially interesting, as markers associated with radiotherapy
treatment outcome for cancer patients have not been previ-
ously described. However, further studies in larger datasets
Figure 1. Kaplan–Meier plots of cumulative survival for breast cancer death in 10 years. Absolute uncorrected survival rates are presented
among the pooled data set (HR51.62, 95% CI 1.07–2.46, pCox’s regression50.023; (a) and among ER-positive patients (HR51.8, 95% CI
1.09–2.98, pCox’s regression50.021; (b) Results for survival analysis among familial cases (C) from Helsinki.
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are needed to validate the radiotherapy outcome for FANCM
mutation carriers.
FANCM is a multifunctional protein, acting as an anchor
protein for both Fanconi Anemia and Bloom syndrome com-
plexes, two molecular pathways that functionally overlap in
these genetic disorders.30–32 As a part of the FA pathway,
FANCM operates in the interstrand crosslink repair to facili-
tate various DNA repair processes, such as homologous recom-
bination and non-homologous end-joining (NHEJ)
pathway.30,33 Inactivation of the FA pathway leads to hyper-
sensitivity to DNA crosslinking agents, and in the absence of
FANCM, the formation of the FA and Bloom’s complexes is
unsuccessful and this may explain the tumorigenetic character-
istics of defective FANCM protein.32 Interestingly, in addition
to BRCA-genes, recent studies link several Fanconi anemia
pathway genes also with sensitivity to PARP inhibition, includ-
ing PALB2, RAD51C, and SLX4,34–36 as well as FANCM.35
Mutations in FANCM were found to cause hypersensitivity to
PARP inhibitors, indicating that FANCM actually has a role in
the cellular defense against PARP inhibition.37 This may reﬂect
the several roles FANCM has in cells also outside the Fanconi
Anemia pathway, including replisome stability and cell cycle
checkpoint activation when DNA repair is needed.38–40
Taking the DNA repair functions of FANCM in consider-
ation, we examined nuclear immunohistochemical staining
Figure 2. Forest plot of hazard ratios and their confidence intervals
for the FANCM c.5101 C> T mutation in the pooled data set and in
different subgroups including the clinical factors and conventional
cancer treatments. The Cox proportional hazard model was used
for 10-year breast-cancer specific survival. Horizontal lines repre-
sent 95% confidence intervals. ER5 estrogen receptor,
PR5progesterone receptor, TN 5triple negative, N5 nodal metas-
tasis status. All cases5 all cases after samples with missing data
are excluded.
Table 3. A) Cox’s proportional hazard model to test the interaction between radiotherapy treatment and FANCM c.5101C> T mutation with
breast cancer death as an endpoint; B) Local recurrence as an endpoint
Covariate HR p 95% CI Endpoint
A
Model 1: no interaction Breast cancer death (10 yrs)
RS147021911 1.71 0.011 1.13–2.60
Radiotherapy 0.70 1.0 3 1024 0.58-0.84
Covariate HR p 95% CI Endpoint
Model 2: interaction Breast cancer death (10 yrs)
RS147021911 3.72 7.00 3 1024 1.74-7.95
Radiotherapy 0.72 8.40 3 1024 0.59–0.87
RS147021911:Radiotherapy 0.37 0.032 0.15–0.92
Likelihood ratio test p values 0.040
B
Covariate HR p 95% CI Endpoint
Model 1: no interaction Local recurrence (5 yrs)
RS147021911 1.71 0.298 0.62–4.64
Radiotherapy 0.48 1.05 3 1023 0.31–0.75
Covariate HR p 95% CI Endpoint
Model 2: interaction Local recurrence (5 yrs)
RS147021911 5.96 1.50 3 1023 1.42–25.11
Radiotherapy 0.52 4.05 3 1023 0.33–0.81
RS147021911:Radiotherapy 0.16 0.080 0.02–1.23
Likelihood ratio test p values 0.090
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proﬁles of DNA repair markers of the FANCM c.5101C>T
mutation carriers. Among eight examined markers, the muta-
tion was associated with low expression of poly (ADP-ribose)
marker (PAR), which measures the activity of the PARP
enzymes participating in DNA repair processes in cells,41
indicating that the mutation carriers have decreased PARP-
activity. It must be noted that our immunohistochemical
method measures the overall poly(ADP-ribosyl)ation levels in
tumor nuclei, and is therefore not speciﬁc to any particular
PARP enzyme or biological process. The best known example
of PARylation occurs in response to DNA damage, where
the binding and activity of PARP promotes DNA repair
through the single-strand break (SSB), double-strand break
(DSB), or base excision repair (BER) pathways.42 In the case
of excessive DNA damage, hyper-PARylation may also be a
signal for cell death.43 PARylation has additionally been
reported to play a role in mitosis, chromatin remodeling,
regulation of transcription, and the organization of genomic
regulatory regions via insulator elements.44 We can there-
fore only speculate on the speciﬁc functional signiﬁcance of
the FANCM-associated reduction in PARylation observed in
our breast tumor samples. We did not detect a change in
gamma-H2AX staining, suggesting that a major quantitative
change in overall DNA damage is not the case here. Since
both FANCM and PARP are involved in resolving replica-
tion stress,45–47 it is possible that the FANCM c.5101C>T
mutation-associated reduction in PAR staining indicates a
replication stress sensitive phenotype that would respond
strongly to the extreme replication stress caused by radiation
therapy. While the causal relationship of FANCM with
reduced PARylation levels remains unclear, our data may
have therapeutic implications.27,48 Given the role of FANCM
in resolving replication stress, the FANCM-mutant tumors
may be especially sensitive to drugs that further exacerbate
the extent of replication stress, such as PARP inhibitors.
Based on our present results and the emerging knowledge in
the ﬁeld, we suggest that the subset of FANCM-mutant
tumors may be particularly vulnerable to PARP inhibitors,
used either as a monotherapy or, as our data indicate, com-
bined with radiotherapy. Future preclinical and clinical stud-
ies should test the feasibility of these conceptually plausible
options.
Conclusions
Our ﬁndings indicate that the FANCM c.5101C>T mutation
in Fanconi Anemia pathway associates with the disease out-
come of breast cancer. Based on the large series of Finnish
breast cancer patients, we have shown here that the mutation
carriers have worse long-term survival and increased risk for
local recurrence, however the survival may be improved with
radiotherapy. Further analyses in larger datasets are war-
ranted to clarify the survival effects and functional mecha-
nisms associated with the mutation, especially on the efﬁcacy
of radiotherapy. Such studies may eventually help to under-
stand the biological mechanisms affecting tumor progression
and further support efforts for creating more targeted treat-
ment combinations and risk estimation.
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